Holdings
TCG Crossover Management, LLC
As of Sep 30, 2026, TCG Crossover Management, LLC reported 52 positions worth US$3.29B. Largest: Abivax SA, CG Oncology, Inc. and Amylyx Pharmaceuticals, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Abivax SA | 3.66M | US$363M | −2.34M | Sep 30, 2026 |
| CG Oncology, Inc. | 3.67M | US$260M | no change | Sep 30, 2026 |
| Amylyx Pharmaceuticals, Inc. | 6.24M | US$182M | no change | Sep 30, 2026 |
| Spyre Therapeutics, Inc. | 1.9M | US$169M | no change | Sep 30, 2026 |
| Tango Therapeutics, Inc. | 6.77M | US$169M | −2.31M | Sep 30, 2026 |
| Zai Lab Ltd. | 6.23M | US$164M | +91,454 | Sep 30, 2026 |
| Immunovant, Inc. | 4.46M | US$151M | no change | Sep 30, 2026 |
| Dianthus Therapeutics, Inc. | 1.68M | US$148M | no change | Sep 30, 2026 |
| Kodiak Sciences Inc | 1.45M | US$137M | no change | Sep 30, 2026 |
| Vor Biopharma Inc. | 5.67M | US$108M | no change | Sep 30, 2026 |